My watch list  

Drug Development

Companies Drug Development

Rigontec GmbH, Germany

Rigontec is a leader in the field of RIG-I-activating RNA therapeutics. Using our proprietary RIG-I agonist platform, we are taking advantage of one of the most important pathways of the innate immune system to develop a novel approach to cancer immunotherapy. Rigontec's proprietary agonists specifi more

Pantherna Therapeutics GmbH, Germany

Pantherna Therapeutics is a privately-held biopharmaceutical Company developing first-in-class therapeutics for vascular diseases. Pantherna’s innovative technology platform is based on advanced nanoparticles for the delivery and expression of therapeutic mRNA drugs in the endothelium. Pantherna is more

Inflamalps SA, Switzerland

Inflamalps is a biopharmaceutical company established in Valais, Switzerland Our mission is ‘’to discover and develop novel medicines to treat inflammation with a focus on chronic inflammatory diseases of the eye and of the skin” Our team comprises experienced pharmaceutical industry and biotechnolo more

News Drug Development

  • Leukemia Epigenetics in Focus

    Some severe forms of leukemia develop because proteins on the epigenetic level lose their regulative function. Now, in a broad international collaboration, UK researchers have identified molecules that can effectively inhibit the dysregulated proteins. In the journal Angewandte Chemie, researchers r more

  • Clues to making drugs for "undruggable" targets

    Nicolas Thomä's group at the FMI has joined forces with the group of Benjamin Ebert at Harvard’s Broad Institute to show how thalidomide analogs mediate degradation of many more proteins than previously anticipated. These proteins – zinc finger transcription factors – play a role in cancer and devel more

  • The tightest non-aminoglycoside ligand for the bacterial ribosomal RNA A-site

    A research group at Tohoku University has made a significant discovery with positive implications for the development of bacteria-fighting drugs. The aminoacyl-tRNA site (A-site) of the 16S RNA decoding region in the bacterial ribosome looks promising for a new era of antibiotic drug development. Tr more

All news on drug development

White papers Drug Development

All white papers on drug development

Events Drug Development


Webinar: Cross-competition or Epitope Binning Assays on the Octet HTX System

Epitope binning describes segmentation of a panel of monoclonal antibodies into “bins” based upon the antigen region, or epitope, bound by the antibody using cross-competition assays. It is often performed in novel drug development, in generation of biosimilars, and in selecting reagents for sandwic


Molecular Imaging: A Powerful Translational Tool in Drug Development

In vivo imaging techniques play an increasingly integral role in the drug development process. The applications of in vivo translational imaging are extending further into drug discovery and development and have the potential to considerably accelerate the process, reduce cost and increase 3Rs compl


When and Where to Add PDX Models: IO and Non-IO

With only 5% of cancer drugs being approved, the financial risks to oncology programs are huge. Recently, PDX (patient-derived xenografts) have become one of the preferred approaches for preclinical drug development and biomarker discovery, but when is the best time to introduce them into your progr

All events on drug development

Publications Drug Development

All publications on drug development

Market studies Drug Development

All market studies on drug development

Drug development

Drug development Drug development or preclinical development is defined in many pharmaceutical companies as the process of taking a new chemical lead through the stages necessary to allow it to be tested in human clinical trial s, although a broa ... more


This is where you can add this topic to your personal favourites

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE